For The Better

At their current valuations, they look like worthy long-term investments.

These two big pharma stocks have what it takes to bounce back.

Upstart is still delivering where it counts.

Regulators’ recent announcement has shareholders breathing a sigh of relief.

Don’t let inflation ruin your senior years.

Each has a path toward grabbing a larger portion of its respective market.

The stock is falling in spite of strong future prospects.

Here’s why investors should consider adding C3.ai to their portfolios.

Elon Musk is Dogecoin’s biggest cheerleader. But you should think twice before following his lead.

The veteran telecom company is having a stellar year in many respects, but reason for concern has emerged.

The market may be underestimating just how big of a deal its ad-supported option could become.

The third time could be the charm for the tobacco giant.

This low-cost, diversified fund is building my investment nest egg.

Be careful around the stocks everybody loves.

Shares are down sharply in 2022, but for good reasons.

The LNG producer unveiled its new long-term vision.

And we’ve got a small-cap franchisor of resale stores for you to consider: Winmark.

Michael Meyer, author of “Benjamin Franklin’s Last Bet: The Favorite Founder’s Divisive Death, Enduring Afterlife, and Blueprint for American Prosperity,” helps us learn from this great man.

These companies are benefiting from major long-term tailwinds.